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INTRODUCTION {#jcla21738-sec-0050}
============

Viral infections account for most of the respiratory tract infections in adults and children [1](#jcla21738-bib-0001){ref-type="ref"}. However, the treatment of respiratory tract infections primarily targets a bacterial etiology, and an etiologic diagnosis is not made in many cases [2](#jcla21738-bib-0002){ref-type="ref"}, [3](#jcla21738-bib-0003){ref-type="ref"}. The identification of the causative agents of respiratory infections is important for selecting an appropriate treatment, including antiviral therapy; for avoiding unnecessary antibiotic use and additional testing; and for preventing nosocomial spread [4](#jcla21738-bib-0004){ref-type="ref"}, [5](#jcla21738-bib-0005){ref-type="ref"}, [6](#jcla21738-bib-0006){ref-type="ref"}.

Conventional tests such as viral culture and rapid antigen testing are still useful for their availability in many laboratories, but conventional methods have low sensitivities and specificities relative to molecular methods and are limited to testing for only a subset of respiratory viruses [1](#jcla21738-bib-0001){ref-type="ref"}. Moreover, the causative agents of respiratory viral infections are numerous, and simultaneous infection by more than one virus is present in 5 to 15% of infections [7](#jcla21738-bib-0007){ref-type="ref"}, [8](#jcla21738-bib-0008){ref-type="ref"}, [9](#jcla21738-bib-0009){ref-type="ref"}. Thus, molecular methods that are capable of multiplex detection are beneficial for rapid detection. Various multiplex nucleic acid amplification‐ and microarray‐based methods have been evaluated for the simultaneous detection and identification of multiple respiratory viruses [8](#jcla21738-bib-0008){ref-type="ref"}, [10](#jcla21738-bib-0010){ref-type="ref"}, [11](#jcla21738-bib-0011){ref-type="ref"}. The xTAG Respiratory Virus Panel (RVP) assay (Luminex Corporation, Toronto, Canada) is a suspension microarray that incorporates bead hybridization after multiplex reverse‐transcription PCR (RT‐PCR) and target‐specific primer extension. The Verigene Respiratory Virus Plus (RV+) assay (Nanosphere, Northbrook, IL) detects the nucleic acids of respiratory viruses with gold nanoparticle based probes on a solid microarray after multiplex RT‐PCR. These assays have different targets and principles of detection for viral pathogens. There have been very few studies using the Verigene RV+ assay [12](#jcla21738-bib-0012){ref-type="ref"}, [13](#jcla21738-bib-0013){ref-type="ref"}, a solid microarray for respiratory virus testing and thus, we conducted a study to compare the performance of the Verigene RV+ assay and xTAG RVP assay, a liquid bead array for the detection of common targets of the assays, influenza virus A (INF A), influenza virus B (INF B), and respiratory syncytial virus (RSV), in respiratory specimens of hospitalized patients.

MATERIALS AND METHODS {#jcla21738-sec-0060}
=====================

The respiratory specimens that were submitted to the laboratory for multiple respiratory virus testing from December 2010 through February 2013 were included. A total of 170 respiratory specimens from hospitalized patients suspected of viral respiratory infections were tested with both assays. The samples consisted of nasopharyngeal aspirates or swabs (NAS) (*n* = 116), trans tracheal aspirates (TTA) (*n* = 21), bronchoalveolar lavage fluid (BAL) (*n* = 12), and other respiratory specimens (*n* = 21). The tests were performed mostly within a week of receipt and in some cases, specimens were stored at −70°C until testing. Specimens from the same patient were included if they were collected more than a week apart. The respiratory viruses and their subtypes that were detected using each assay are shown in Table [1](#jcla21738-tbl-0001){ref-type="table"}. The detection of common target respiratory viruses by two assays, INF A, INF B, and RSV (subtypes A and B), were assessed.

###### 

Target Respiratory Viruses of Each Assay

                            xTAG RVP   Verigene RV+
  ------------------------ ---------- --------------
  Adenovirus                   √      
  CoV                                 
  CoV 229E                     √      
  CoV OC43                     √      
  CoV NL63                     √      
  CoV SARS                     √      
  INF A                        √            √
  Subtype H1                   √            √
  Subtype H3                   √            √
  Subtype H5N1                 √      
  Subtype 2009 H1N1                         √
  INF B                        √            √
  Metapneumovirus              √      
  Parainfluenza virus                 
  Parainfluenza virus 1        √      
  Parainfluenza virus 2        √      
  Parainfluenza virus 3        √      
  Parainfluenza virus 4        √      
  RSV                          √            √
  RSV subtype A                √            √
  RSV subtype B                √            √
  Rhinovirus/enterovirus       √      

Blank denotes viruses not detected by the assay.

CoV, coronavirus.

John Wiley & Sons, Ltd.

Liquid Bead Array xTAG RVP {#jcla21738-sec-0070}
--------------------------

Nucleic acids were extracted from 200 μl of each respiratory specimen and 20 μl of bacteriophage MS2 using the NucliSENS easyMAG automated system (bioMérieux, Basingstoke, UK). The extracts were tested using the xTAG RVP assay according to the manufacturer\'s instructions (Luminex Corporation). In brief, RT‐PCR was performed with 5 μl of the extracted nucleic acid on a PTC‐200 thermal cycler (MJ Research, Waltham, MA). Target‐specific primer extension was performed with 5 μl of RT‐PCR product mixed with 15 μl of master mix. Twenty microliters of RVP bead mix was aliquoted into each well of the plate and 3.5 μl of the product was added to the corresponding wells. The beads and the PCR products were incubated and the reporter solution was added. A Luminex 200 (Luminex Corporation) was used to detect the mean fluorescence intensity of the products. Positive and negative controls were included and the results were interpreted according to the manufacturer\'s recommendation by the mean fluorescence intensity.

Solid Microarray Verigene RV+ {#jcla21738-sec-0080}
-----------------------------

For each respiratory specimen, 200 μl was loaded into the sample well on the extraction tray of Verigene RV+ assay, and the tray was inserted into the Verigene Processor SP. Viral RNA isolation and multiplex RT‐PCR were performed in the processor. The virus‐specific amplicons were captured by complementary oligonucleotides, and gold nanoparticle probe hybridization was performed in the processor. After the test was finished, the RV+ test cartridge was placed into the Verigene Reader for analysis. Six to twelve spots were used for each virus, and the presence or absence of each virus was interpreted according to the microarray spots detected.

Result Comparison {#jcla21738-sec-0090}
-----------------

The analytical performances of the two assays were analyzed with the golden standard, the \"final\" result. The final results were decided upon the results of various assays performed for each specimen in routine clinical practice, including xTAG RVP, Verigene RV+, multiplex real‐time RT‐PCR [14](#jcla21738-bib-0014){ref-type="ref"}, or immunochromatographic tests, Asan Easy Test Influenza A/B (Asan Pharmaceutical, Seoul, Korea), Binax Now RSV (Binax Inc., Scarborough, ME). Each specimen was tested for three or more of these assays including xTAG RVP and Verigene RV+, and the results in concordance by two or more of the performed assay were considered "final." The sensitivity and specificity were compared by receiver operating characteristic (ROC) analysis. The assay concordance for identifying each target virus was calculated using kappa statistics. The overall agreement of each assay for the detection of respiratory viruses regardless of the virus type was analyzed using the McNemar test. MedCalc (MedCalc Software, Mariakerke, Belgium) was used for the statistical analysis of the data.

RESULTS {#jcla21738-sec-0100}
=======

Of the 170 specimens tested, xTAG RVP identified respiratory viruses in 120 specimens (70.6%). Thirty‐three specimens were identified positive for viruses other than INF and RSV. In respiratory specimens positive for INF or RSV (*n* = 87, 51.2% (19.4%)), single respiratory virus was identified in most of the specimens (*n* = 83, 95.4%): INF A in 37 specimens, INF B in 16 specimens, RSV A in 25 specimens, and RSV B in 5 specimens. For INF A, H1 type was identified in 1 specimen, H3 in 22 specimens, and other types in 14 specimens. Coinfection of two respiratory viruses was detected in four specimens: INF A + RSV (*n* = 2), INF A + INF B (*n* = 1), INF B + RSV (*n* = 1).

By Verigene RV+, which identified INF and RSV only, 84 specimens (49.4%) were negative for those respiratory viruses. Single respiratory viruses were identified in 80 specimens (47.1%): INF A in 36 specimens, INF B in 14 specimens, RSV A in 25 specimens, and RSV B in 5 specimens. Coinfection of two respiratory viruses was detected in six specimens (3.5%): INF A + INF B (*n* = 3), INF A + RSV (*n* = 3).

Analytical Performance of the Assays {#jcla21738-sec-0110}
------------------------------------

Analytical performance of the assays was evaluated by comparing the assay results to the \"final\" results. The sensitivities, specificities, and area under the curve (AUC) for the detection of different respiratory viruses by the assays are shown in Table [2](#jcla21738-tbl-0002){ref-type="table"}. The AUC for INF A was higher with xTAG RVP than Verigene RV+ but not statistically significant (*P* = 0.364). The sensitivity and specificity for INF B was same for both assays. For RSV, the AUC of xTAG RVP was not statistically different with Verigene RV+ (*P* = 0.317).

###### 

Sensitivity and Specificity of xTAG RVP and Verigene RV+

               xTAG RVP (*n* = 170)    Verigene RV+ (*n* = 170)                          
  ------------ ---------------------- -------------------------- ------- ------- ------- -------
  INF A (41)   97.6                             100.0             0.988  95.1    98.5    0.968
  INF B (17)   100.0                             99.4             0.997  100.0   99.4    0.997
  RSV (34)     100.0                            100.0             1.000  97.1    100.0   0.985

John Wiley & Sons, Ltd.

The eight discordant results excluding the discrepant results for subtype assignment for INF A by two assays are shown in Table [3](#jcla21738-tbl-0003){ref-type="table"}. xTAG RVP yielded one false‐positive result for INF B and a false‐negative result for INF A. Verigene RV+ showed three false‐positive results (two INF A, one INF B) and three false‐negative results (two INF A, one RSV). The specimen type of the discordant results were NAS (*n* = 5), BAL (*n* = 1), TTA (*n* = 1), and other undefined respiratory specimen (*n* = 1). The false‐positive/negative results were evaluated according to the specimen types (NAS vs. other). xTAG RVP showed two false‐positive/negative results with NAS specimens, but none in other type of specimens. Verigene RV+ showed three false‐positive/negative results with NAS samples and three with other type of respiratory specimens. There were no significant differences in the discordant rates between specimen types by xTAG RVP or Verigene RV+ (*P* = 0.712).

###### 

Discordant Results by xTAG RVP and Verigene RV+

  Specimen no.    Specimen type  Results by xTAG RVP    Results by Verigene RV+   Final
  -------------- --------------- ---------------------- ------------------------- ----------------------
  1                    TTA       INF A, RSV subtype B   INF A subtype 2009 H1N1   INF A, RSV subtype B
  2                    NAS       INF B                  INF A, INF B              INF B
  3                    BAL       INF B                  INF A, INF B              INF B
  4                    NAS       Negative               INF A subtype H3          INF A
  5                    NAS       INF A                  Negative                  INF A
  6                    NAS       INF A                  Negative                  INF A
  7                   Other      RSV subtype A          RSV subtype A, INF B      RSV subtype A
  8                    NAS       RSV subtype A, INF B   RSV subtype A             RSV subtype A

BAL, bronchoalveolar lavage; NAS, nasopharyngeal swab; TTA, transtracheal aspirate.

John Wiley & Sons, Ltd.

Direct comparison of the results by two assays for the virus or virus subtypes are shown in Table [4](#jcla21738-tbl-0004){ref-type="table"}. The viruses detected in common were INF A and its subtypes H1 and H3, unclassifiable, INF B and RSV subtypes A and B. The overall results for detecting respiratory viruses, regardless of the virus type, were not significantly different (*P* = 1.000). The results for INF B and RSV subtype A were concordant, but subtype results for INF A and RSV subtype B showed discordant results. With respect to the number of viral pathogens detected by the two assays, the xTAG RVP detected two viruses simultaneously in five specimens (2.9%, two INF A + RSV B, one INF A + INF B, one INF A + RSV A, one INF B + RSV A coinfection), but the Verigene RV+ detected coinfection in six specimens (3.5%, three INF A + INF B, one INF A + RSV A, one INF A + RSV B, one INF B + RSV A coinfection). The kappa coefficient was 0.908 for the xTAG RVP and Verigene RV+.

###### 

Detection Results for xTAG RVP and Verigene RV+

  Target          Results by xTAG RVP/Verigene RV+ (*n* = 170, %)                       
  --------------- ------------------------------------------------- --------- --------- ------------
  INF A                                                                                 
  Subtype H1      1 (0.6)                                           0 (0.0)   0 (0.0)   169 (99.4)
  Subtype H3      24 (14.1)                                         0 (0.0)   3 (1.8)   143 (84.1)
  Other           13 (7.6)                                          2 (1.2)   3 (1.2)   152 (89.4)
  INF B           17 (10.0)                                         1 (0.6)   1 (0.6)   153 (88.8)
  RSV subtype A   27 (15.9)                                         0 (0.0)   0 (0.0)   143 (84.1)
  RSV subtype B   6 (3.5)                                           1 (0.6)   0 (0.0)   163 (95.9)

John Wiley & Sons, Ltd.

DISCUSSION {#jcla21738-sec-0120}
==========

We compared the performance of a liquid bead array (xTAG RVP) and a solid microarray (Verigene RV+) by testing 170 respiratory specimens from hospitalized patients for INF and RSV. The two assays showed high sensitivities and specificities for INF A, INF B, and RSV, which are clinically important respiratory viruses [15](#jcla21738-bib-0015){ref-type="ref"}, [16](#jcla21738-bib-0016){ref-type="ref"} and were able to detect multiple pathogens in multiplex reactions.

The assays showed no significant difference in the AUC for detecting INF A, INF B, and RSV, and the sensitivity and specificity were similar to the previous studies with xTAG RVP and Verigene RV+ [13](#jcla21738-bib-0013){ref-type="ref"}, [17](#jcla21738-bib-0017){ref-type="ref"}, [18](#jcla21738-bib-0018){ref-type="ref"}, [19](#jcla21738-bib-0019){ref-type="ref"}, [20](#jcla21738-bib-0020){ref-type="ref"}. There were eight discordant results and many of those results (62.5%) were due to false‐positive or negative‐results in detecting coinfection of viruses. These discrepancies may be due to the different sensitivities and specificities of each assay on different targets in multiplex reactions. Regarding one false‐positive INF A by Verigene RV+, only Verigene RV+ had detected INF A among the assays performed with this sample. However, this result was from a patient previously diagnosed with coinfection of INF A and INF B by xTAG RVP and Verigene RV+, thus although our golden standard, the final result was INF A, the conclusion of false positivity of this particular sample with Verigene RV+ may be questionable. In addition, the discordant results may be due to the low viral load of the samples as suggested by previous studies [17](#jcla21738-bib-0017){ref-type="ref"}, [19](#jcla21738-bib-0019){ref-type="ref"}. Thus, measuring the viral load of the discordant results may give answers to the discrepancies in some cases.

The direct comparison of the results by two assays showed good agreement with kappa coefficient of 0.908. Many of the discordances were due to subtype assignment for INF A as shown in Table [4](#jcla21738-tbl-0004){ref-type="table"}. Among eight discrepant cases, INF A was not detected in three cases and five showed different results. INF A subtype was not assigned in three specimens by xTAG RVP and those results showed relatively low mean fluorescence intensity (\<1,000), which may be a cause for discrepancies.

Coinfection of respiratory viruses was detected in four specimens (2.4%) according to the \"final\" result, and these specimens were detected with coinfection of two respiratory viruses. The number of specimens with coinfection and the number of simultaneously detected viruses were both lower than the previous studies [19](#jcla21738-bib-0019){ref-type="ref"}, [21](#jcla21738-bib-0021){ref-type="ref"}, [22](#jcla21738-bib-0022){ref-type="ref"}, [23](#jcla21738-bib-0023){ref-type="ref"}. This difference is due to the limited number of target viruses that are detected commonly by the two assays. With respect to the number of viruses detected simultaneously, only coinfection with two viruses were observed, whereas previous studies have reported small numbers of cases with coinfection by three to six different viruses [19](#jcla21738-bib-0019){ref-type="ref"}, [21](#jcla21738-bib-0021){ref-type="ref"}, [23](#jcla21738-bib-0023){ref-type="ref"}. Those studies used assays with broader ranges of target viruses, but it has been suggested that the increased numbers of viruses detected may also be due to the detection of noncausal viruses [24](#jcla21738-bib-0024){ref-type="ref"}. Coinfection by respiratory viruses are being detected in more cases when using multiplex assays, but research on the clinical relevance of viral coinfection is limited and should be expanded.

Despite a few discrepant results, there was a high degree of overall agreement in detecting the presence or absence of respiratory viruses between the two assays. Moreover, the kappa coefficients were 0.908, which suggests "almost perfect" or "good" agreement in identifying common target viruses using these methods [25](#jcla21738-bib-0025){ref-type="ref"}.

A comparison of the results of the assays showed that there was a high degree of overall agreement for the commonly detected respiratory viruses, and therefore, these assays could be used based on the needs of the laboratories with respect to the target viruses, sample sizes, and available resources. xTAG RVP analyzes broader range of respiratory viruses and has moderate‐to‐high throughput but the complexity is higher and the time required for the result is longer. On the other hand, Verigene RV+ tests only INF A/B and RSV but requires less hands‐on time of the technicians and has less complexity compared to the xTAG RVP, and shorter time is required for the result [2](#jcla21738-bib-0002){ref-type="ref"}, [12](#jcla21738-bib-0012){ref-type="ref"}. xTAG RVP would be useful in larger hospitals or laboratories requiring high‐throughput assays and has experience in molecular testing, in hospital settings with many critically ill patients. Verigene RV+ may be useful in smaller laboratories or hospitals with lesser technicians, less experience in molecular testing or in hospitals with outpatient‐based settings. Studies comparing the Verigene RV+ with other commercial multiplex respiratory virus assays are limited, and this study shows that the solid microarray Verigene RV+ is a reliable method for the detection of the INF and RSV.

In conclusion, the performance of xTAG RVP and Verigne RV+ in identifying common respiratory viruses was good, and depending on the target viruses and the size of the specimen to be tested for respiratory viruses, specific assays can be selected.
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